- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01178385
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
February 25, 2013 updated by: University of South Florida
Autism spectrum disorders affect as many as 1 out of 150 children and are related to significant impairment in social, adaptive, and school functioning.
Co-occurring conditions, such as anxiety, are common and may cause substantial distress and impairment beyond that caused by the autism diagnosis.
Although effective interventions have been developed for typically developing youth with anxiety disorders, this approach needs to be adapted for children with autism.
Accordingly, we are proposing a randomized controlled trial to examine the effectiveness of CBT relative to treatment as usual (TAU) in 46 youth ages 7-11 with autism spectrum disorders and comorbid anxiety disorder(s).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Autism spectrum disorders affect as many as 1 out of 150 children (Centers for Disease Control, 2007), with many higher-functioning children not being diagnosed until elementary school or later (Fombonne, 2003).
Significant impairment in social, adaptive, and school functioning is prevalent and longstanding (Howlin et al., 2004).
In addition, comorbid psychological disorders are common in the ASD population (Simonoff et al., 2008), and may cause substantial distress and impairment beyond that caused by the ASD diagnosis.
Comorbid anxiety disorders, in particular, affect as many as 80% of children and adolescents with ASD (Bellini, 2004; de Bruin et al., 2007; Klin et al., 2005; Muris et al., 1998).
Although efficacious interventions have been developed for otherwise typically developing youth with anxiety disorders, the linguistic; cognitive; and social characteristics of ASD may render standard treatment approaches less effective for children with ASD (Volkmar & Klin, 2000).
Thus, there is a clinical need for the modification of existing treatment modalities for this unique group.
To date, few studies have experimentally tested the efficacy of CBT for youth with a comorbid presentation of anxiety and ASD.
This gap in the literature is of particular concern given the prevalence of comorbid anxiety among children, consequences of untreated anxiety, unknown efficacy of antidepressant medication for anxiety in ASD, and potential safety and tolerability issues related to medication use.
Accordingly, we are proposing a randomized controlled trial to examine the efficacy of CBT relative to treatment as usual (TAU) in 46 youth ages 7-11 with ASD and comorbid anxiety disorder(s).
In the proposed grant, we will: (1) examine the acute efficacy of CBT relative to TAU, and (2) evaluate the short-term maintenance of treatment gains.
Forty-six children (ages 7-11 years) with ASD and comorbid anxiety disorder(s) will be randomly assigned to one of the two treatment conditions.
Primary outcomes will be assessed by an independent evaluator, and will include change in anxiety symptom severity; response rates; and remission rates.
Considering the rising number of children diagnosed with ASD, our proposed work toward the advent of an efficacious CBT protocol will provide a timely contribution to public health efforts.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
St. Petersburg, Florida, United States, 33701
- Rothman Center for Neuropsychiatry, University of South Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 11 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatient children with an autism spectrum disorder (see #2 below) between the ages 7-11years.
- Meets criteria for a diagnosis of autism, Asperger syndrome (AS), or PDD-NOS using scores from the Autism Diagnostic Interview-Revised and Autism Diagnostic Observation Schedule.
- Meets DSM-IV criteria for a diagnosis of one of the following anxiety disorders: separation anxiety disorder (SAD), generalized anxiety disorder (GAD), social phobia, or obsessive compulsive disorder (OCD) as determined by the ADIS-IV-C/P (with CSR 4) and all available information.
- Minimum score of 14 on the PARS Severity Scale; this score indicates clinically significant anxiety symptom severity (RUPP, 2002) and has been used in recent major clinical trials (e.g., Walkup et al., 2008).
- Child has a Full Scale and Verbal Comprehension IQ > 70 as assessed on a commonly used IQ test.
- Subjects with co-morbid depression, ADHD, tic disorder or disruptive behavior disorders will be acceptable as long as the anxiety disorder is primary (i.e., most impairing/distressing).
Exclusion Criteria:
- Receiving concurrent psychotherapy, social skills training, or behavioral interventions (e.g., applied behavior analysis). Families will have the option of discontinuing such services to enroll in the study. Those randomized to TAU will be able to continue or initiate psychosocial interventions (psychotherapy, social skills training, applied behavior analysis, or family therapy) whereas those randomized to CBT will not receive these interventions concurrent with CBT.
- New Treatments: Initiation of an antidepressant within 12 weeks before study enrollment or an antipsychotic 8 weeks before study enrollment. No new alternative medications, nutritionals or therapeutic diets within 8 weeks of study enrollment.
- Established Treatment changes: Any change in established psychotropic medication (e.g., antidepressants, anxioloytics) within 8 weeks before study enrollment, or any change in alternative medications that might have behavioral effects within 6 weeks prior to the study baseline assessment. Those randomized to TAU may make medication changes following randomization, including starting a medication; those randomized to CBT will remain stable on medications during the study.
- (a) Current clinically significant suicidality or (b) individuals who have engaged in suicidal behaviors within 6 months will be excluded and referred for appropriate clinical intervention.
- Lifetime DSM-IV bipolar, schizophrenia or schizoaffective disorders; or Substance abuse in past 6 months.
- Unwillingness of parents to make the commitment to accompany their child for multiple study visits.
- Presence of a significant and/or unstable medical illness which might lead to hospitalization during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive-behavioral therapy
Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders.
The BIACA intervention program is flexible in nature and employs a modular format.
Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
|
Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders.
The BIACA intervention program is flexible in nature and employs a modular format.
Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
Other Names:
|
Active Comparator: Treatment as Usual
Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions).
Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored.
Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
|
Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions).
Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored.
Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms)
Time Frame: After an average of 16 weeks (Post-treatment)
|
This scale assesses the severity of anxiety symptoms.
The scale ranges from 0 (minimum score) to 25 (maximum score).
Higher scores reflect more severe anxiety symptoms; lower scores reflect lower anxiety severity.
There are no subscales to this measure.
|
After an average of 16 weeks (Post-treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety Disorders Interview Schedule Highest Anxiety Clincian Severity Rating (Measures the Severity of the Child's Anxiety Symptoms)
Time Frame: After an average of 16 weeks (Post-treatment)
|
This is a measure of severity of the child's primary anxiety disorder.
The maximum rating is 8, the minimum rating is 0. Higher scores correspond to more severe anxiety.
|
After an average of 16 weeks (Post-treatment)
|
Clinical Global Impression - Severity Scale (This Scale Measures the Severity of the Child's Anxiety Symptoms).
Time Frame: After an average of 16 weeks (Post-treatment)
|
This scale measures severity of the child's overall anxiety presentation.
The minimum rating is 0, the maximum is 6.
Higher scores correspond to greater anxiety; lower scores correspond to less severe anxiety.
There are no subscales for this measure.
|
After an average of 16 weeks (Post-treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
August 5, 2010
First Submitted That Met QC Criteria
August 7, 2010
First Posted (Estimate)
August 10, 2010
Study Record Updates
Last Update Posted (Estimate)
April 2, 2013
Last Update Submitted That Met QC Criteria
February 25, 2013
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACH-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on Cognitive-behavioral therapy
-
Eleos HealthMissouri Department of Mental HealthCompletedMood Disorders | Anxiety DisordersUnited States
-
Regionsenter for barn og unges psykiske helseThe Research Council of NorwayCompletedGeneralized Anxiety Disorder | Social Phobia | Separation Anxiety DisorderNorway
-
Claremont McKenna CollegeUniversity of California, Los AngelesCompleted
-
University of South FloridaObsessive Compulsive FoundationCompletedObsessive Compulsive Disorder | Stepped Care Cognitive Behavioral TherapyUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of RochesterNational Institute of Nursing Research (NINR)CompletedDepression | Sleep | Stress Disorders, Post-TraumaticUnited States
-
University of PittsburghWithdrawnPsychosis | Prodromal Symptoms | Prodromal Stage | Prodromal StatesUnited States
-
Duke UniversityCompleted
-
The University of Texas Health Science Center at...59th Medical Wing; Brooke Army Medical Center; South Texas Veterans Health Care...CompletedCombat Disorders | Post-Traumatic Stress Disorders | Stress DisordersUnited States
-
University of PittsburghCompletedDepression | Anxiety | Sickle Cell DiseaseUnited States